Robotic-Assisted Navigation Bronchoscopy as a Paradigm Shift in Peripheral Lung Access

Benn, Bryan S.; Romero, Arthur Oliver; Lum, Mendy; Krishna, Ganesh

doi:10.1007/s00408-021-00421-1

Cited by 79 publications

(73 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A sample size of 100 lesions is not large. However, it matches or exceeds the sample sizes of similar, previously published studies [20,[29][30][31].…”

Section: Discussionsupporting

confidence: 83%

“…Two systems are currently on the market: the Ion TM Endoluminal Robotic Bronchoscopy Platform (Intuitive Surgical© [Sunnyvale, CA, USA]) and the Monarch TM Platform (Auris Health© [Redwood City, CA, USA]) [29,30]. A prospective database study by Benn et al [31] using the Ion TM Endoluminal Robotic Bronchoscopy System with CBCT for secondary confirmation showed an immediate diagnostic yield of 83% and a procedural sensitivity of 84%. At present, a multicenter but single-arm, industry-sponsored observational study assessing the clinical utility and performance of the Ion TM Endoluminal Bronchoscopy System is underway [32].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Sight Unseen: Diagnostic Yield and Safety Outcomes of a Novel Multimodality Navigation Bronchoscopy Platform with Real-Time Target Acquisition

et al. 2021

View full text Add to dashboard Cite

Background: Several advanced bronchoscopy platforms are currently available, but the clinical data supporting their use vary. Electromagnetic navigation bronchoscopy (ENB) remains the dominant technology; it is limited by its reliance on preoperative computed tomography, which only approximates patient anatomy during the procedure. Recently, ENB was enhanced with the (1) addition of digital tomosynthesis-based navigation correction, (2) improvements in planning algorithms, and (3) continuous real-time guidance (Illumisite™; Medtronic, Minneapolis, MN, USA). There are currently no clinical data on the diagnostic yield and safety profile of this system. Objectives: The primary objective of this study is to describe the diagnostic yield of the first 100 pulmonary parenchymal lesions sampled using the multimodality navigation bronchoscopy (MNB) platform. The secondary objective is to describe safety. Methods: In this single-center prospective observational study, a database was maintained to track patient, procedural, and outcome data for the first 100 consecutive lesions sampled using the MNB platform at an academic quaternary referral center. Descriptive statistics and univariate and multivariate analyses are reported. Results: The overall diagnostic yield of samples acquired was 79% (79/100). In the cohort where digital tomosynthesis was used, the diagnostic yield was 83% (69/83). Sensitivity for malignancy was 71% (52/73). Overall complication rates were low: pneumothorax (n = 3, 3%) and bleeding requiring intervention (n = 2, 2%). There were no procedural-related hospital admissions. Conclusions: The MNB system performed favorably. Platform superiority cannot be established without future prospective and comparative studies.

show abstract

“…A sample size of 100 lesions is not large. However, it matches or exceeds the sample sizes of similar, previously published studies [20,[29][30][31].…”

Section: Discussionsupporting

confidence: 83%

Section: Discussionmentioning

confidence: 99%

Sight Unseen: Diagnostic Yield and Safety Outcomes of a Novel Multimodality Navigation Bronchoscopy Platform with Real-Time Target Acquisition

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In recent years, there have been notable advancements in the guidance technologies for peripheral bronchoscopy, including newer electromagnetic navigation platforms, cone beam CT, augmented fluoroscopy, digital tomosynthesis, and robot-assisted bronchoscopy. [1][2][3][4][5][6][7] As a result, multiple recent trials evaluating the performance of these technologies have been reported. The most frequently employed assessment metric is diagnostic accuracy, frequently termed diagnostic yield (DY) in the bronchoscopy literature, yet there remains no standardized approach to measurement of this outcome in studies of bronchoscopy.…”

mentioning

confidence: 99%

The Impact of Alternative Approaches to Diagnostic Yield Calculation in Studies of Bronchoscopy

Vachani

Maldonado

Laxmanan

et al. 2022

Chest

View full text Add to dashboard Cite

“…Many contributions in the ever-expanding area of interventional pulmonology were received in 2021. The best of those studies investigated transthoracic needle aspiration [ 49 ], percutaneous lung biopsy [ 50 ], robotic-assisted [ 51 ] and 4D electromagnetic navigation bronchoscopy [ 52 ], transbronchial cryobiopsy [ 53 , 54 ], and therapeutic intervention with endobronchial coils [ 55 ].…”

mentioning

confidence: 99%

LUNG Year in Review: 2021

Dicpinigaitis

2022

Lung

View full text Add to dashboard Cite

Robotic-Assisted Navigation Bronchoscopy as a Paradigm Shift in Peripheral Lung Access

Cited by 79 publications

References 34 publications

Sight Unseen: Diagnostic Yield and Safety Outcomes of a Novel Multimodality Navigation Bronchoscopy Platform with Real-Time Target Acquisition

Sight Unseen: Diagnostic Yield and Safety Outcomes of a Novel Multimodality Navigation Bronchoscopy Platform with Real-Time Target Acquisition

The Impact of Alternative Approaches to Diagnostic Yield Calculation in Studies of Bronchoscopy

LUNG Year in Review: 2021

Contact Info

Product

Resources

About